Thursday 29 Feb 2024
main news image

KUALA LUMPUR (May 27): Sinovac Biotech Ltd has confirmed that Pharmaniaga Bhd is the sole distributor of its Covid-19 vaccine in Malaysia – both in fill-and-finish and finished forms.

In a video statement, the Chinese pharmaceutical giant’s chief business officer Helen Yang said it enjoys a very good working relationship with Pharmaniaga.

“We are dealing with Pharmaniaga through a government-to-government arrangement, without any involvement of other third parties.

"We have been meeting each other’s obligations and all contractual deliveries are on schedule,” she said.

Sinovac had appointed Pharmaniaga as an exclusive distributor of the Sinovac vaccine in Malaysia early this year.

Yang stressed that all Sinovac Covid-19 vaccines exported from China to Malaysia must go through the product registration holder in Malaysia, which is Pharmaniaga.

In the video. Yang also pledged Sinovac's commitment to develop and deploy Covid-19 vaccines worldwide to combat Covid-19.

“I want to thank the great efforts of our partner Pharmaniaga and the Malaysian government to help make that happen.

"We are looking forward to the day that the use of vaccines can end the world pandemic,” she concluded.

Sinovac is one of three brands of vaccines currently under Malaysia’s National Immunisation Programme (PICK), the others being Pfizer and AstraZeneca.

On Wednesday (May 26), Pharmaniaga announced that its plans to import 10 million more doses of the Sinovac Covid-19 finished vaccine from China.

Pharmaniaga has so far received one million doses of the finished vaccine from the Chinese company.

Pharmaniaga has projected that it will be able to supply a total of 8.6 million Sinovac vaccine doses by the end of June, and plans to order another 10 million doses of the finished vaccine.

Shares of Pharmaniaga closed 7.64% or 34 sen higher at RM4.79 today, valuing the group at RM1.25 billion. The counter saw 4.3 million shares traded.

Edited ByS Kanagaraju
      Text Size